ストックスクリーナーアプリを入手
4.72
1.87%
-0.09
アフターアワーズ：
4.71
-0.010
-0.21%
前日終値:
$4.81
開ける：
$4.81
24時間の取引高:
2.46M
Relative Volume:
1.25
時価総額：
$1.51B
収益：
$248.37M
当期純損益:
$11.74M
株価収益率:
94.40
EPS:
0.05
ネットキャッシュフロー:
$18.24M
1週間 パフォーマンス:
-1.26%
1か月 パフォーマンス:
+1.29%
6か月 パフォーマンス:
-32.18%
1年 パフォーマンス:
+7.03%
1日の値動き範囲:
$4.645
$4.81
1週間の範囲:
$4.42
$4.87
52週間の値動き範囲:
$4.34
$7.63
Mannkind Corp Stock (MNKD) Company Profile
MNKD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
4.72 | 1.51B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-02-10 | 開始されました | Wedbush | Outperform |
| 2024-12-20 | 開始されました | Wells Fargo | Overweight |
| 2024-12-19 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-06-13 | 開始されました | Rodman & Renshaw | Buy |
| 2023-10-10 | 開始されました | Wedbush | Outperform |
| 2021-05-14 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | 開始されました | Oppenheimer | Outperform |
| 2019-10-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-05-14 | 開始されました | BTIG Research | Buy |
| 2019-03-04 | 開始されました | SVB Leerink | Outperform |
| 2019-02-22 | 開始されました | SVB Leerink | Outperform |
| 2018-02-28 | ダウングレード | Maxim Group | Hold → Sell |
| 2017-11-01 | ダウングレード | Maxim Group | Buy → Hold |
| 2017-10-10 | 開始されました | H.C. Wainwright | Buy |
| 2017-10-06 | 繰り返されました | Maxim Group | Buy |
| 2017-08-11 | 開始されました | Maxim Group | Buy |
| 2016-05-10 | 繰り返されました | Piper Jaffray | Underweight |
| 2016-05-10 | 繰り返されました | RBC Capital Mkts | Underperform |
| 2016-01-06 | 繰り返されました | Piper Jaffray | Underweight |
| 2016-01-06 | 繰り返されました | RBC Capital Mkts | Underperform |
| 2015-11-04 | ダウングレード | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | ダウングレード | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2015-05-11 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2015-05-11 | 繰り返されました | MLV & Co | Hold |
| 2015-04-16 | 繰り返されました | RBC Capital Mkts | Outperform |
すべてを表示
Mannkind Corp (MNKD) 最新ニュース
MannKind Corporation (NASDAQ:MNKD) Q1 2025 Earnings Call Transcript - Insider Monkey
MannKind Corporation (MNKD): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Decoding MannKind Corp (MNKD): A Strategic SWOT Insight - GuruFocus
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
MannKind: Q1 Earnings Snapshot - MySA
Earnings call transcript: MannKind Q1 2025 revenue beats, stock dips - Investing.com
MannKind (MNKD) Surpasses Q1 Revenue Expectations with Strong Growth | MNKD Stock News - GuruFocus
MannKind Corp Q1 2025 Earnings: EPS Meets Estimates at $0.04, Revenue Surpasses Expectations at $78 Million - GuruFocus
MannKind Corporation Reports First Quarter 2025 Financial Results - TradingView
MANNKIND CORP SEC 10-Q Report - TradingView
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
MannKind Corp (MNKD) Q1 2025 Earnings Report Preview: What To Expect - Yahoo Finance
MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025 - The Globe and Mail
The Potential Rise in the Price of Mannkind Corp (MNKD) following insiders activity - knoxdaily.com
Solidion Technology Inc’s latest rating changes from various analysts - knoxdaily.com
MNKD (Mannkind Corp) may reap gains as insiders became active recently - knoxdaily.com
Mannkind Corp (MNKD) is looking forward to a strong quarter - Sete News
Is MannKind Corporation (MNKD) the Best Quality Penny Stock to Buy According to Hedge Funds? (READY TO EDIT2) - Insider Monkey
Is MannKind Corp. (NASDAQ:MNKD) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey
13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey
MannKind (NASDAQ:MNKD) Upgraded at Mizuho - Defense World
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Mizuho sets MannKind stock Outperform with $12 target - Investing.com
Mizuho sets MannKind stock Outperform with $12 target By Investing.com - Investing.com India
Diabetes Meets Racing: MannKind's Game-Changing Partnership With Type 1 Diabetic IndyCar Star - Stock Titan
MannKind To Support Conor Daly - Speed Sport
FTNT Stock Sees Surge of Approximately 1.11% in Last Five Days - knoxdaily.com
Why It's Worth Keeping An Eye On MannKind - RTTNews
Cantor maintains Overweight rating on MannKind stock at $9 target - Investing.com
Inhalable Biologics Industry Report 2025: World Market to Nearly Triple in Size by 2030, Reaching $10.06 Billion at a CAGR of 17.6% - Yahoo Finance
MannKind at Barclays Healthcare Conference: Strategic Growth and Innovation - Investing.com India
MAC Lung Disease Market Statistics Expected to Experience Major - openPR
MannKind Corporation Showcases Positive Outcomes of Inhaled Insulin at ATTD 2025 with Anticipated sNDA Filing for Pediatric Use in 2025 - Nasdaq
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22 - Yahoo Finance
AllPennyStocks.com News: Companies Looking Towards Future Revenue with New Diabetes Therapies - ACCESS Newswire
Commit To Purchase MannKind At $3, Earn 13.3% Using Options - Nasdaq
Non- Tuberculous Mycobacterial Infections Market on Track for Major Expansion by 2034, According to DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharma - Barchart
Non- Tuberculous Mycobacterial Infections Market on Track - openPR
MannKind’s (MNKD) Outperform Rating Reiterated at Wedbush - Defense World
MannKind Stock Surges After-Hours On Q4 Revenue Beat, Debt Reduction As Retail Investors Celebrate ‘Amazing Comeback’ - MSN
MannKind Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance
MannKind Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question - Seeking Alpha
Mannkind Corp (MNKD) 財務データ
収益
当期純利益
現金流量
EPS
Mannkind Corp (MNKD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Binder Steven B. | Director |
Nov 22 '24 |
Sale |
6.89 |
67,536 |
465,323 |
1,075,026 |
3.01%
大文字化:
|
ボリューム (24 時間):